1. Home
  2. RDHL vs MBIO Comparison

RDHL vs MBIO Comparison

Compare RDHL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.81

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.73

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDHL
MBIO
Founded
2009
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.6M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
RDHL
MBIO
Price
$0.81
$0.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
148.8K
63.5K
Earning Date
04-27-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$381.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.53
52 Week High
$3.31
$7.00

Technical Indicators

Market Signals
Indicator
RDHL
MBIO
Relative Strength Index (RSI) 40.38 42.95
Support Level $0.76 $0.58
Resistance Level $0.89 $0.82
Average True Range (ATR) 0.08 0.09
MACD -0.02 -0.00
Stochastic Oscillator 12.08 8.97

Price Performance

Historical Comparison
RDHL
MBIO

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: